Trial Profile
Pharmacokinetics and Safety of the Novel Sulfactam Antibiotic BAL30072 after Single Ascending Dose Infusions in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Sep 2011
Price :
$35
*
At a glance
- Drugs BAL 30072 (Primary)
- Indications Gram-negative infections
- Focus Adverse reactions; Pharmacokinetics
- 17 Sep 2011 Results presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.
- 25 May 2011 Positive tolerability and pharmacokinetic results reported in a Basilea Pharmaceuticals media release.
- 25 May 2011 Status changed from recruiting to completed, according to information in a Basilea Pharmaceuticals media release.